This is a transformative readout for CYTK — the first positive Phase 3 trial in nHCM with no approved therapies. Expect significant upside at open. Key catalysts ahead: FDA submission timing (likely H2 2026), pricing/reimbursement for expanded indication, and potential partnership or M&A interest given the now de-risked pipeline. Monitor the investor call on May 5 at 8:00 AM ET for regulatory timeline details.
Price Chart
Executive Summary
Cytokinetics announced positive topline results from the ACACIA-HCM Phase 3 trial of aficamten in non-obstructive HCM, meeting both dual primary endpoints with statistically significant improvements in KCCQ-CSS (p=0.021) and pVO2 (p=0.003) vs placebo at Week 36. This is a major catalyst as there are currently no approved therapies for nHCM, potentially expanding aficamten's addressable market by ~50% (half of all HCM patients).
Key Facts
- ACACIA-HCM met dual primary endpoints: KCCQ-CSS improvement of 3.0 points (p=0.021) and pVO2 improvement of 0.67 mL/kg/min (p=0.003) vs placebo at Week 36
- Statistically significant improvements (p<0.001) in key secondary endpoints: NYHA class, composite z-score of VE/VCO2 and pVO2, and NT-proBNP
- No new safety signals; LVEF <50% occurred in 10% of aficamten vs 1% placebo patients, with 2 serious heart failure adverse events in aficamten arm
- Aficamten (MYQORZO) already approved in U.S., EU, and China for obstructive HCM; this trial targets the ~50% of HCM patients with non-obstructive disease who have no approved therapies
- Company plans to discuss results with FDA and other regulatory authorities for potential label expansion
Financial Impact
Potential to double aficamten's addressable patient population from ~150,000 diagnosed oHCM patients to ~300,000 diagnosed HCM patients in the U.S., with an estimated 400,000-800,000 undiagnosed patients
Risk Factors
- Safety signal: 10% LVEF <50% and 2 serious heart failure events on aficamten may prompt FDA scrutiny despite no new safety signals
- Regulatory risk: FDA could require additional data or limit label to specific nHCM subpopulations
- Competition: Bristol Myers Squibb's mavacamten (Camzyos) is approved for oHCM but not nHCM; could potentially pursue nHCM indication
- Commercial execution risk: Expanding from oHCM to nHCM requires new physician education and patient identification
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287549 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access